---
created: 2026-05-10
status: archived-originals
source: cardiac-imaging-valve-slimming
---

# Cardiac Imaging / Valve Cluster Original Text Archive — 2026-05-10

This archive preserves the full pre-consolidation text of overlapping cardiac imaging, CT screening, and aortic-valve pages before the active KB was slimmed. The active report should use `ldncp-advanced-imaging.md` as the canonical Cardiac Imaging & Valve Plan; this file is provenance/recovery, not active guidance.


---

## Original `ldncp-advanced-imaging.md`

```markdown
---
topic: LDNCP and Advanced Cardiac Imaging for Lp(a) Patients
tags: [cardiovascular, imaging, cta, calcium-score, ldncp, lp(a), ai-qct, plaque-characterization, vulnerable-plaque]
priority: important
last_updated: 2026-05-08
confidence: medium-high
abstract: >-
  CAC can miss low-density non-calcified plaque, the phenotype most relevant to high Lp(a)
  concern. CAC remains the practical first step; positive CAC, symptoms, or clinician concern
  should move the discussion toward CCTA/AI-QCT. RPPH now has a real public coronary-CT route
  signal, including CTA Coronary in a heart package, but report contents still need confirmation.
  Echocardiography matters separately for Lp(a)-linked aortic-valve risk.
open_questions:
  - Should Dag use CAC as the minimum anchor test, or jump straight to CCTA if symptoms/logistics make that more sensible?
  - Is AI-QCT actually available at Bumrungrad, Bangkok Hospital, or Bangkok Heart Hospital, and what does the report include?
  - What did any prior CAC/CCTA/echo show, if done?
---

# LDNCP and Advanced Cardiac Imaging for Lp(a) Patients

## Summary

Lp(a) 838.6 mg/L creates a specific imaging problem: CAC measures **calcified** plaque, while Lp(a) is associated with non-calcified, low-attenuation, high-risk plaque features that CAC can miss. CAC is still useful as the low-friction first anchor, but it is not the whole answer. CCTA answers the coronary plaque-composition question; echocardiography answers the separate Lp(a)-linked aortic-valve question.

The April 2025 episode of sudden epigastric/upper-abdominal pain with dizziness, sweating, and left arm/hand symptoms lowers the threshold for cardiac evaluation if that symptom pattern recurs. With current bleeding/occult-blood risk, imaging also matters because documented plaque could create harder cardiology/GI tradeoffs around aspirin or other antithrombotics.

## Current Profile

| Factor | Relevance |
|---|---|
| Lp(a) 838.6 mg/L | Very high inherited risk marker; rough mg/dL conversion should stay approximate unless a future assay reports nmol/L directly. |
| LDL 2.04 mmol/L / ApoB 66.31 mg/dL on atorvastatin 20 mg | Atherogenic particle burden is reasonably controlled, but this does not erase Lp(a)-linked plaque/valve risk. |
| Smoking on/off, active again in April 2026 | Raises the priority of plaque and endothelial-risk clarification. |
| Early-April 2025 pain episode | Not proof of coronary disease, but the autonomic + arm symptoms mean recurrence should be treated as possible cardiac/ACS until same-day ECG + high-sensitivity troponin assessment rules it out. |
| Diverticular bleeding / occult stool blood | Raises the cost of antiplatelet decisions if plaque is found. |

## What Each Test Answers

| Test | Answers | Does not answer | Role in this case |
|---|---|---|---|
| CAC score | Calcified coronary plaque burden; low-cost risk anchor. | Non-calcified plaque, stenosis, plaque composition, valve status. | Default first coronary test if asymptomatic and logistics matter. CAC >0 documents calcified coronary plaque / subclinical atherosclerosis and strengthens cardiology/escalation discussions. |
| CCTA | Coronary anatomy, stenosis, calcified and non-calcified plaque, high-risk features. | Aortic-valve hemodynamics; not always quantitative enough for plaque subtype volume. | Best next step if symptoms recur, CAC is positive, or cardiology wants direct plaque characterization. |
| CCTA + AI-QCT / quantitative plaque analysis | Non-calcified plaque volume, low-attenuation plaque volume, total plaque burden, composition tracking. | Availability and report contents vary by center. | Ideal if available and affordable, but should be confirmed before paying a premium. |
| Transthoracic echo | Aortic-valve morphology/stenosis and left-ventricular function. | Coronary plaque. | Reasonable baseline because Lp(a) causes calcific aortic-valve disease. |
| OCT / invasive imaging | Microscopic plaque/cap features during coronary angiography. | Screening. | Not relevant unless CCTA/angiography finds a lesion where invasive characterization would change treatment. |

## CAC Blind Spot

CAC = 0 is reassuring for short-term calcified plaque burden, but not a blanket all-clear in very high Lp(a). The missing category is low-density non-calcified plaque (LDNCP): lipid-rich plaque detectable by CCTA/quantitative analysis but invisible to calcium scoring.

Statins complicate interpretation in the opposite direction: they can increase plaque calcification as a stabilization/healing pattern while reducing non-calcified plaque risk. A rising CAC on statin therapy is therefore not automatically “worse plaque biology”; the useful question is whether active non-calcified / low-attenuation plaque remains.

## Evidence Anchors

| Evidence area | Main finding | Source anchors |
|---|---|---|
| Lp(a) and non-calcified plaque | Higher Lp(a) is associated with CCTA high-risk coronary attributes, low-attenuation/non-calcified plaque signals, and adverse outcomes in several cohorts. | PMID: 36503252; PMID: 38692827; PMID: 42054506 |
| Lp(a)-driven plaque phenotype | Newer deep-phenotyping work supports a vulnerable/non-calcified plaque signature in Lp(a)-driven CVD. | PMID: 41908166 |
| Lp(a) and events after AMI/PCI | Lp(a) plus lesion complexity predicted adverse events in AMI/PCI cohorts. | PMID: 41729960 |
| Statins and plaque composition | Statins can reduce non-calcified plaque progression while increasing plaque calcification as a stabilization/healing pattern. | PMID: 29909109; PMID: 32160786 |
| AI-QCT / quantitative CCTA | AI-enabled or quantitative CCTA plaque analysis is an emerging add-on for plaque/hemodynamic risk characterization; report contents and validation vary by vendor/center. | PMID: 38752951; PMCID: PMC11683154 |
| Aortic valve disease | Genetic, cohort, consensus, and progression evidence links Lp(a) to calcific aortic-valve stenosis; surveillance logic now lives in [Aortic Valve + Vascular Aging](#sec-aortic-valve-vascular-aging). | PMID: 23388002; PMID: 24161338; PMID: 39018080 |

## Imaging Decision Pathway

| Situation | Next step | Interpretation |
|---|---|---|
| Asymptomatic and cost/logistics matter | CAC + baseline echo | Low-friction way to document calcified plaque burden and valve status. |
| CAC = 0 | Continue aggressive risk-factor control; consider CCTA only if symptoms/high suspicion/logistics justify it. | Reassuring, not exculpatory. Non-calcified plaque and valve risk are not fully closed. |
| CAC 1–99 | Cardiology discussion; CCTA if plaque composition would change treatment intensity. | Documented early plaque. |
| CAC 100–399 | Cardiology review; CCTA or functional testing depending on symptoms and clinician plan. | Established plaque burden. |
| CAC ≥400 | Specialist-directed cardiac workup. | High plaque burden; screening logic is over. |
| Symptoms recur with sweating/dizziness/arm symptoms | Same-day ECG + high-sensitivity troponin assessment; CCTA/cardiology evaluation after acute rule-out. | Possible ACS rule-out first. |
| High-quality CCTA/AI-QCT is readily accessible and affordable | Consider CCTA first after cardiology/shared decision. | Skips staged CAC-first approach and answers plaque composition directly. |

## What to Ask For

If ordering cardiac CT, the useful wording is:

- “CCTA with plaque characterization and stenosis assessment.”
- “If available, quantitative or AI-assisted plaque analysis.”
- “Please report non-calcified plaque, low-attenuation plaque, positive remodeling, napkin-ring sign, spotty calcification, and stenosis severity.”

Avoid asking CT to diagnose true thin-cap fibroatheroma. TCFA is a histology/intravascular-imaging concept; CCTA reports related high-risk features.

## Local / Regional Access

RPPH now publicly lists a 128-slice CT scanner and a CT coronary-screening package, and its 2026 Heart Packages poster lists **CTA Coronary** in Platinum. Phnom Penh therefore has a real coronary-CT route signal. The unresolved part is still report content: confirm CAC scoring vs contrast CCTA vs both, ECG gating, stenosis fields, and whether non-calcified/high-risk plaque features are reported.

Bangkok remains the fallback for higher-end CCTA or quantitative plaque analysis. Before booking, confirm the report contents rather than the marketing label: non-calcified plaque volume, low-attenuation plaque volume, total plaque burden, stenosis, and high-risk features. If AI-QCT is not available, a high-quality standard CCTA read by an experienced cardiac radiologist is still much more informative than CAC alone for non-calcified plaque.

## Practical Takeaways

1. **Echo is the separate baseline test** because CAC/CCTA do not assess Lp(a)-linked aortic-valve disease.
2. **CAC is the simplest coronary anchor** if asymptomatic and logistics/cost matter.
3. **CCTA becomes more attractive** if CAC is positive, symptoms recur, or plaque composition would change cardiology management now.
4. **CAC = 0 lowers near-term concern but does not erase Lp(a) risk.** Continue ApoB/LDL control, smoking cessation, BP control, and symptom vigilance.
5. **If plaque is found, antiplatelet decisions are not automatic** because diverticular/occult bleeding risk changes the net-benefit discussion.

## Research Trace

- Research mode: clinical decision synthesis from existing KB evidence and prior Lp(a)/CCTA/AI-QCT literature; compactness rewrite 2026-04-29.
- Evidence anchors: CCTA plaque phenotype and Lp(a) (PMID: 36503252; PMID: 38692827; PMID: 42054506; PMID: 41908166); statin plaque-composition changes (PMID: 29909109; PMID: 32160786); AI-QCT / quantitative CCTA risk characterization (PMID: 38752951; PMCID: PMC11683154); Lp(a)-aortic valve evidence (PMID: 23388002; PMID: 24161338; PMID: 39018080).
- Unresolved gaps: current Phnom Penh CCTA plaque-characterization capability; whether Bangkok centers provide true quantitative/AI plaque reports; whether any prior CAC/CCTA/echo exists.

```


---

## Original `ct-scan-screening.md`

```markdown
---
topic: CT Scan Preventive Screening
tags: [ct-scan, coronary-artery-calcium, calcium-score, ldct, cardiovascular, lung-cancer, screening, cta]
priority: important
last_updated: 2026-05-08
confidence: high
abstract: >-
  CAC is the lowest-friction coronary plaque anchor for this high-Lp(a) profile; CAC=0 is
  reassuring but not a full Lp(a) all-clear because CCTA can reveal non-calcified plaque.
  RPPH public material now supports a real local coronary-CT route (128-slice CT, CT coronary-screening
  page, and CTA Coronary in the Platinum heart package), but CAC-vs-CCTA deliverables and plaque-report
  detail still need confirmation before booking. LDCT, abdomen CT, and full-body CT stay guideline- or
  symptom-conditional rather than broad screening.
open_questions: [Has Dag ever had a prior CAC scan? Does RPPH provide standalone CAC, contrast CCTA, or both, and does the local report include Agatston score plus stenosis/non-calcified/high-risk plaque fields?]
---

# CT Scan Preventive Screening for This Profile

## Summary

Blood markers do not show actual plaque. With very high Lp(a), active/recent smoking, and no documented CAC/CCTA/echo result, the useful imaging question is narrow: document coronary plaque burden and aortic-valve baseline without drifting into broad “scan everything” screening.

## Decision table

| Scan / route | What it answers | Use here | Main source anchors |
|---|---|---|---|
| **CAC score** | Calcified coronary plaque burden; low-friction risk reclassification. | Default first coronary CT if asymptomatic and cost/logistics matter. Any CAC >0 makes lipid-intensification/cardiology discussions more concrete. | ACC/AHA cholesterol + primary-prevention guidance (PMID: 30423393; 30879355); Lp(a)-CAC meta-analysis (PMID: 38300625). |
| **CAC = 0** | Low near-term calcified plaque burden. | Reassuring, but not a full all-clear for very high Lp(a): non-calcified plaque and aortic-valve disease remain separate questions. Continue ApoB/LDL, BP, and smoking work. | Miami Heart Study CCTA: with CAC=0, any plaque was 24.2% with elevated Lp(a) vs 14.2% without (PMID: 39012945). |
| **CCTA** | Coronary anatomy, stenosis, calcified + non-calcified plaque, high-risk features. | Consider if symptoms recur, CAC is positive, cardiology wants anatomy/plaque detail, or high-quality CCTA is easily available. Not automatic for every asymptomatic high-Lp(a) patient. | ESC chronic coronary syndrome guideline (PMID: 39210710); Miami Heart Study (PMID: 39012945). |
| **CCTA + quantitative/AI plaque analysis** | Total plaque, non-calcified/low-attenuation plaque volume, composition tracking. | Useful if report contents are real and affordable; verify before paying a premium. | Existing imaging owner: `ldncp-advanced-imaging.md`. |
| **Baseline echocardiogram** | Aortic valve sclerosis/stenosis and LV function. | Separate from CT: reasonable baseline because Lp(a) is linked to calcific aortic-valve disease. | [Aortic Valve + Vascular Aging](#sec-aortic-valve-vascular-aging). |
| **LDCT lung screening** | Lung-cancer screening in high-risk smokers. | Only if careful pack-year reconstruction reaches guideline threshold or clinician orders it for symptoms. Current cloud-doc history looks below threshold. | USPSTF 2021: age 50-80, >=20 pack-years, current smoker or quit <15 years. |
| **Abdomen/pelvis CT** | Acute diverticulitis complications, obstruction, perforation, focal structural problems. | Not for routine bloating or occult stool blood alone. Use for acute persistent focal/systemic pain, fever, obstruction, abscess/perforation concern, weight loss, or clinician-directed workup. | ACR left-lower-quadrant pain / suspected diverticulitis criteria (PMID: 31054740). |
| **Full-body CT** | Broad incidental finding hunt. | Do not do as screening. High incidentaloma/follow-up burden; no proven net benefit in asymptomatic people. | FDA whole-body CT warning; ACR total-body screening caution. |

## CAC score interpretation

| Score | Interpretation for this profile | What changes |
|---|---|---|
| **0** | No detectable calcified coronary plaque. Helpful reassurance, not permission to relax risk control. | Continue statin/ApoB control, smoking cessation, BP profile, and echo. CCTA only if symptoms, specialist concern, or direct plaque-composition question justifies it. |
| **1-99** | Subclinical plaque exists despite acceptable blood numbers. | Cardiology discussion; tighten LDL/ApoB target discussion; CCTA only if anatomy/plaque detail would change treatment. |
| **100-399** | Meaningful coronary plaque burden. | Cardiology review; consider CCTA or functional testing per symptoms/plan; PCSK9/ezetimibe discussion becomes more concrete. Aspirin still requires GI-bleeding risk review. |
| **>=400** | High calcified plaque burden. | Specialist-directed coronary workup. Screening logic ends; manage as high-risk coronary disease context. |

## Symptom override

If the early-April 2025 pattern recurs — sudden intense epigastric/chest/upper-abdominal pain with sweating, dizziness, nausea, or arm/hand symptoms — that is not a screening question. Use same-day ECG + high-sensitivity troponin / possible-ACS rule-out logic first; CCTA can follow after acute rule-out if cardiology wants anatomy.

## Local access boundary

Keep logistics in `phnom-penh-medical-access.md`; this page keeps only decision-relevant facts.

- **RPPH:** official pages list a 128-slice CT scanner and a CT coronary-screening package; the 2026 Heart Packages poster also lists **CTA Coronary** in Platinum. This confirms a local coronary-CT route, but not the exact standalone deliverable.
- **Ask before booking:** “Is this non-contrast coronary calcium scoring, contrast CCTA, or both? Is ECG gating used? Do you report Agatston score, stenosis, non-calcified plaque, low-attenuation plaque, positive remodeling, spotty calcification, napkin-ring sign, and valve/aorta observations? What is the radiation dose and standalone/package price?”
- **Bangkok fallback:** Use Bangkok only if Phnom Penh cannot answer the CAC/CCTA/report-content question cleanly or if quantitative/AI plaque analysis is the specific goal.

## Radiation / burden framing

| Scan | Typical burden | Practical meaning |
|---|---|---|
| CAC | Low radiation, often around ~1 mSv; no contrast. | Low-friction anchor, but not zero-risk and not annual by default. |
| LDCT chest | Low radiation, repeated annually only if screening-eligible. | Use Lung-RADS/Fleischner-style follow-up if nodules are found. |
| CCTA | Higher and protocol-dependent radiation; IV contrast; heart-rate control may be needed. | More information, more burden; use when the answer changes management. |
| Full-body CT | Broad radiation + incidentalomas. | Poor tradeoff for asymptomatic screening. |

## References

- ACC/AHA cholesterol guideline, CAC for risk refinement: PMID 30423393.
- ACC/AHA primary-prevention guideline, CAC as risk-decision aid and aspirin caution: PMID 30879355.
- Lp(a) and CAC in asymptomatic adults meta-analysis: PMID 38300625.
- Miami Heart Study CCTA plaque findings, including CAC=0 subgroup: PMID 39012945.
- ESC chronic coronary syndrome guideline for CCTA/diagnostic pathway: PMID 39210710.
- USPSTF 2021 lung-cancer LDCT recommendation: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
- ACR suspected diverticulitis / LLQ pain imaging: PMID 31054740.
- FDA whole-body CT screening warning: https://www.fda.gov/radiation-emitting-products/medical-x-ray-imaging/full-body-ct-scans-what-you-need-know
- RPPH 128-slice CT, CT coronary-screening package, and Heart Packages/CTA Coronary source trail: https://www.royalphnompenhhospital.com/our-technology-detail/10, https://www.royalphnompenhhospital.com/package-detail/18, and https://www.royalphnompenhhospital.com/package-detail/19

```


---

## Original `aortic-valve-vascular-aging.md`

```markdown
---
topic: Aortic Valve and Vascular Aging in Very High Lp(a)
tags: [cardiovascular, lp(a), aortic-stenosis, echocardiography, blood-pressure, vascular-aging]
priority: important
last_updated: 2026-05-04
confidence: medium-high
abstract: >-
  Very high Lp(a) makes aortic-valve baseline assessment a separate question from coronary calcium.
  CAC=0 can be reassuring for near-term calcified coronary plaque, but it does not assess aortic
  sclerosis/stenosis, LV response, pulse pressure, or arterial-stiffness context. The practical route
  is baseline transthoracic echocardiography plus a clean 7-day BP profile; repeat intervals depend
  on whether the valve is normal, sclerotic, or already stenotic.
related_topics: [lp-a.md, prevention-status-cvd-burden.md, ldncp-advanced-imaging.md, ct-scan-screening.md, blood-pressure-profile.md]
open_questions: [Does baseline echocardiography show aortic sclerosis or stenosis? What are the 7-day home BP average and pulse pressure?]
---

# Aortic Valve and Vascular Aging in Very High Lp(a)

## SearchPlan

- **Question type:** diagnosis / monitoring / risk translation.
- **Question:** In a 51-year-old man with Lp(a) 838.6 mg/L, what should baseline echo, aortic-valve surveillance, pulse pressure, BP variability, arterial stiffness, and CAC=0 boundaries change?
- **Dag-specific context:** very high inherited Lp(a), ApoB about 66 mg/dL on atorvastatin, active/recent smoking, no documented CAC/CCTA/echo result in the cloud doc, BP profile not yet documented, and GI bleeding risk that makes antithrombotic escalation costly.
- **Concepts searched:** Lp(a) and calcific aortic-valve disease, aortic stenosis progression, echocardiographic surveillance intervals, pulse pressure, BP variability, arterial stiffness / pulse-wave velocity, CAC=0 limitations.
- **Target sources:** EAS Lp(a) consensus, ESC/EACTS valve guideline, ACC/AHA valve guidance summaries, PubMed cohort/genetic studies, systematic reviews/meta-analyses, and existing KB imaging/BP owners.
- **Stop condition:** define a compact monitoring branch table without duplicating the CAC/CCTA or BP-protocol owners.

## Summary

Lp(a) has two cardiovascular tracks here:

1. **Coronary plaque track:** CAC and CCTA answer calcified plaque, non-calcified plaque, stenosis, and high-risk plaque morphology.
2. **Aortic-valve / vascular-aging track:** transthoracic echocardiography answers aortic sclerosis/stenosis, valve gradients, valve area, LV hypertrophy/function, and aortic-root observations; home BP supplies average BP and pulse pressure.

A CAC score of 0 would be useful but incomplete. It lowers near-term concern about calcified coronary plaque; it does **not** close the Lp(a)-linked aortic-valve question and does not measure BP, pulse pressure, LV response, or arterial stiffness.

## Monitoring branch table

| Finding | Meaning | Next monitoring step | What changes prevention intensity |
|---|---|---|---|
| No echo yet | Valve status unknown | Get one baseline transthoracic echo when logistics allow; include aortic valve morphology/calcification, Vmax, mean gradient, AVA if measurable, LV size/function, LVH, aortic root/ascending aorta | Establishes whether Lp(a) has visible valve target-organ disease |
| Normal valve / no LVH | Good baseline; no formal Lp(a)-specific rescan interval exists | Repeat only if murmur/symptoms develop, BP becomes high, or clinician chooses a 3-5 year high-Lp(a) surveillance check | Keeps focus on smoking, BP, ApoB/LDL, and coronary imaging rather than repeated echo |
| Aortic sclerosis / calcification without stenosis | Lp(a)-consistent valve signal, but not hemodynamically severe | Cardiology-selected interval, commonly a few years; sooner if murmur/symptoms, rising pulse pressure, or report suggests progression risk | Reinforces aggressive risk-factor control; no aspirin indication by itself |
| Mild aortic stenosis | Early hemodynamic disease | ESC guidance allows 2-3 year follow-up in younger mild AS without significant calcification; with heavy calcification/high Lp(a), use cardiologist interval | Stronger reason to keep LDL/ApoB/BP/smoking optimized and avoid missing progression |
| Moderate aortic stenosis | Prognosis can be worse than old assumptions, especially with calcification | At least annual reassessment per ESC; ACC/AHA-style intervals are often 1-2 years | Cardiology follow-up becomes active, not optional |
| Severe aortic stenosis | Screening is over; symptom and intervention timing dominate | At least every 6 months and specialist/valve-clinic pathway | Valve disease becomes a major management axis |
| Wide pulse pressure or high average BP | Vascular aging / afterload signal; may accelerate LV/valve burden indirectly | Finish standardized 7-day home BP; consider ABPM if home/office conflict, morning hypertension, or nocturnal concern | BP control may become as important as lipid intensification |

## BP, pulse pressure, and arterial stiffness

Do not chase arterial-stiffness gadgets before the basic BP dataset exists. The higher-yield sequence is:

1. **7-day home BP average** from a validated upper-arm cuff.
2. **Pulse pressure** from the same readings: systolic minus diastolic. Repeated wide pulse pressure is not diagnostic by itself, but it is a useful vascular-aging clue to bring to cardiology, especially if echo shows LVH, aortic sclerosis/stenosis, or aortic dilation.
3. **ABPM** if home BP suggests masked/morning/nocturnal hypertension or if office and home readings conflict.
4. **Formal pulse-wave velocity / arterial-stiffness testing** only if a cardiology or preventive clinic offers it as part of a broader plan. Current Lp(a)-specific arterial-stiffness evidence is much weaker and less actionable than BP, echo, CAC/CCTA, and smoking abstinence.

BP variability matters as a risk signal, but the immediate use is mundane: avoid cherry-picking readings, average days 2-7, and look for a reproducible morning/evening pattern. One jumpy week during caffeine withdrawal, illness, bad sleep, or stress should not be overinterpreted without repeat data.

## CAC=0 boundary

CAC=0 would be reassuring for calcified coronary plaque, not for everything Lp(a) can do. It would mean:

- lower near-term coronary event concern than CAC-positive high-Lp(a) profiles
- no reason to relax ApoB/LDL, smoking abstinence, BP measurement/control, or symptom vigilance
- no answer on aortic sclerosis/stenosis because CAC is not an echo
- CCTA remains conditional: symptoms, clinician concern, positive future CAC, or a deliberate decision to measure non-calcified plaque

## Practical order for this profile

1. Finish or start the **7-day BP profile** during the clean experiment window.
2. Arrange a **baseline transthoracic echo** when practical in Phnom Penh; RPPH/Rung Reung-style cardiology routes are reasonable local leads.
3. Use **CAC/CCTA** for the coronary-plaque branch, not as a valve substitute.
4. If echo is normal, avoid turning valve surveillance into a frequent anxiety scan; repeat by symptom/murmur/BP trigger or a clinician-selected multi-year interval.
5. If sclerosis/stenosis is present, let the echo severity set the surveillance interval; high Lp(a) makes progression vigilance more credible, but there is still no proven self-directed Lp(a)-valve drug today.

## Evidence anchors

| Evidence area | Finding | Source anchors |
|---|---|---|
| Lp(a) consensus | Lp(a) is causally/continuously associated with ASCVD and aortic valve stenosis; manage global risk factors aggressively while specific therapies await outcomes/access. | EAS consensus PMID: 36036785 |
| Genetic/cohort valve evidence | LPA variants and high Lp(a) are associated with aortic-valve calcification/stenosis. | NEJM genetics PMID: 23388002; Copenhagen general-population AVS PMID: 24161338 |
| Progression once AS exists | 2024 meta-analysis found higher Lp(a) associated with faster hemodynamic AS progression: peak velocity and mean gradient, not clearly valve area. | PMID: 39018080 |
| Mechanism | Lp(a)-carried oxidized phospholipids are linked to valve calcification and AS progression. | PMID: 26361154; PMID: 31047003 |
| Echo surveillance | ESC/EACTS valve guidance: severe AS at least 6-monthly; moderate degenerative AS at least annually; younger mild AS without significant calcification every 2-3 years. | ESC/EACTS guideline PMID: 34453165 |
| BP variability | Visit-to-visit BP variability associates with CVD/mortality in meta-analyses, but the actionable first step is standardized BP collection and treatment of sustained hypertension. | PMID: 27906836 |
| Arterial stiffness | Lp(a)-arterial stiffness evidence is inconsistent and less decision-grade than BP/echo/CAC/CCTA; a 2025 young-FH MRI study found no significant cPWV association. | PMCID: PMC11901005 |

## Research Trace

- **Research date:** 2026-05-04.
- **Integration classification:** INTEGRATE as a new cardiovascular owner because aortic-valve surveillance was previously scattered across Lp(a), CT/CCTA, and prevention-status pages.
- **Search pass:** cloud doc, KB index, `lp-a.md`, `ldncp-advanced-imaging.md`, `blood-pressure-profile.md`, `prevention-status-cvd-burden.md`, PubMed E-utilities, ESC/EACTS valve guideline, EAS Lp(a) consensus, ACC journal scan of the 2024 AS progression meta-analysis.
- **Decision impact:** baseline echo becomes a distinct cardiovascular baseline, not an optional footnote to CAC; pulse pressure is interpreted through the BP profile rather than separate consumer testing; CAC=0 is explicitly coronary-only reassurance.
- **Next review trigger:** baseline echo result, 7-day BP/pulse-pressure profile, new Lp(a)-lowering valve-outcome trial data, or updated valve-surveillance guideline.

```